Olmesartan Medoxmil

Olmesartan Medoxomil serves as a pivotal pharmaceutical intermediate and a critical active pharmaceutical ingredient (API) for the treatment of hypertension. As a prodrug, Olmesartan Medoxomil itself is inactive; however, it is completely converted to the active angiotensin II receptor blocker, olmesartan, during absorption from the gastrointestinal tract . This process is facilitated by the medoxomil ester group on Olmesartan Medoxomil, which is designed to enhance oral bioavailability while protecting the active carboxylic acid moiety from degradation . In the body, Olmesartan Medoxomil's active form, olmesartan, provides a selective and potent blockade of the AT1 receptor, leading to vasodilation and a reduction in blood pressure. This makes Olmesartan Medoxomil a cornerstone therapy for managing hypertension and is widely recognized for its efficacy, safety, and long-lasting effects.

Product Parameters

Bioactivity

The hydrolysate of Olmesartan Medoxomil (CS-866) is Olmesartan, which is a selective AT1 subtype angiotensin II receptor antagonist.

In Vitro Study

Olmesartan Medoxomil significantly reduces the content of hydroxyproline in the liver, the mRNA expression of collagen α1(I), α-smooth muscle actin (α-SMA) and transforming growth factor-β1 (TGF-β1) in plasma. Olmesartan Medoxomil is a prodrug containing an ester moiety. After oral administration, it is rapidly cleaved to release the active form Olmesartan (RNH-6270). Olmesartan is a highly potent, competitive, and selective antagonist of all AT1 receptors, and has almost no antagonistic effect on AT2 and AT4 receptors.

In Vivo Studies

In conscious rats, Olmesartan exerts a rapid and sustained inhibitory effect on all induced pressor responses. Oral olmesartan medoxomil also inhibits the full pressor response, but its action is slower compared with intravenous administration. In several rat and dog models, Olmesartan exhibits a dose-dependent antihypertensive effect, with the most pronounced effect observed in models with high plasma renin when compared with normal or low renin phenotypes. In addition to its antihypertensive effect, oral olmesartan medoxomil demonstrates beneficial effects in animal models of various types of nephropathy and heart failure, and exerts an anti-atherosclerotic effect in hyperlipidemic animals. In rats, oral olmesartan medoxomil dose-dependently ameliorates histopathological and biochemical injuries in rat colon, with an effect equivalent to or even superior to that of the standard agent Sulfasalazine. In rats, oral olmesartan medoxomil significantly reduces the induction of hypoxic pulmonary heart disease, which is observed not only by echocardiography, but also in terms of brain natriuretic peptide (BNP) levels in chronically hypoxic rats, and reduces the induction of TGF-β and endothelin gene expression in molecular studies.

Contact Us

Securing high-quality Olmesartan Medoxomil for your hypertension API manufacturing or cardiovascular research program should be straightforward. Cosperpharm makes it simple—reach out to our team today to discuss your requirements and request a quote.